Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Recruiting

I'm Interested

Trial ID: NCT03391778

Purpose

This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.

Official Title

Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies

Stanford Investigator(s)

Kristen N Ganjoo
Kristen N Ganjoo

Professor of Medicine (Oncology)

Eligibility

Inclusion Criteria:

* Participants who have received at least one dose of ADP adoptive cell therapy agent.
* Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it.
* Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy.
* Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
* The investigator is responsible for review of medical history.
* Capable of giving signed informed consent.

Exclusion Criteria:

- None

Intervention(s):

biological: ADP adoptive cell therapy

Recruiting

I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Ileana Aguilar Torres
650-724-1388

New Trial Alerts